Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

A Novel Index of Assessing Atherosclerosis Regression and Plaque Stabilization


詳細技術說明

UC San Diego researchers have invented a novel index of atherosclerosis regression that is determined by measuring the plasma content of oxidized phospholipids. The index could provide valuable information to physicians who would use this index to measure the efficacy of treatment with statins or new anti-atherogenic drugs.


附加資料

Patent Number: US8129123B2
Application Number: US2005244300A
Inventor: Tsimikas, Sotirios | Witztum, Joseph L.
Priority Date: 5 Oct 2004
Priority Number: US8129123B2
Application Date: 5 Oct 2005
Publication Date: 6 Mar 2012
IPC Current: G01N003353
US Class: 4350071 | 43500792 | 43500794 | 436501 | 436518
Assignee Applicant: The Regents of the University of California
Title: Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios
Usefulness: Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios
Summary: The method is useful for determining whether therapy is effective for treating coronary artery disease (claimed).
Novelty: Determining whether therapy is effective for treating coronary artery disease, by determining oxidized phospholipid and apoB levels in samples obtained before and after administration of therapy, and calculating atherogenesis index


主要類別

診斷/治療


細分類別

其他疾病


申請號碼

8129123


其他

Related Materials

  1. See the published article INNOVATION: From lab to product: a blood test's story.
  2. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96.

Tech ID/UC Case

19643/2005-037-0


Related Cases

2005-037-0, 2009-236-1, 2009-236-2


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版